Evidence map›Paper›PMID 32856987›Full record

ArticleEpigenetics2021

Germline DNMT3A mutation in familial acute myeloid leukaemia.

Courtney D DiNardo, Hannah C Beird, Marcos Estecio, Swanand Hardikar, Koichi Takahashi, Sarah A Bannon, Gautam Borthakur, Elias Jabbour, Curtis Gumbs, Joseph D Khoury and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epigenetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. The dual role of autophagy in acute myeloid leukemia.Journal of hematology & oncology · 2022
    Review
  5. Review
  6. NovelCancers · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Courtney D DiNardoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hannah C BeirdDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-5078-534X
Marcos EstecioDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Swanand HardikarDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Koichi TakahashiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sarah A BannonDepartment of Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gautam BorthakurDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Curtis GumbsDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joseph D KhouryCenter for Cancer Epigenetics, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mark RoutbortCenter for Cancer Epigenetics, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ting GongDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kimie KondoDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hagop KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Taiping ChenDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
P Andrew FutrealDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Modeling ICF syndrome in mice: Role of Zbtb24 in DNA methylation and antibody productionR01AI121403 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHEN, TAIPING · 2016 to 2020
$2.0M
NCI NIH HHS P30 CA016672NIAID NIH HHS R01 AI121403
6 · The paper itself

Abstract

Acute myeloid leukaemia (AML) is a heterogeneous myeloid malignancy characterized by recurrent clonal events, including mutations in epigenetically relevant genes such as

Indexed as

Germ-Line MutationLeukemia, Myeloid, AcuteAdultDNA (Cytosine-5-)-MethyltransferasesDNA MethylationDNA Methyltransferase 3AGerm CellsHumansMutationNeoplasm Recurrence, LocalDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanAMLDNMT3Agermlinehereditarypredisposition

Identifiers

PMID32856987
PMCPMC8078744
OpenAlexW3082271932

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.